Skip to main content
OpenTrials
Completed

NCT Number: NCT05732909

The Metabolic Effects of β-hydroxybutyrate on Working Skeletal Muscle

The goal of this clinical trial is to test ketone bodies in healthy elderly and young individuals. The main question it aims to answer are:

• Do ketone bodies improve skeletal muscle function?

Participants will ingest a ketone monoester and skeletal muscle function will then be evaluated by:

* Special magnetic imaging techniques * Intravenous infusion of tracer-marked nutrients * Performance tests on a ergometer bike and in a dynamometer

Researchers will compare the outcomes between within the young and elderly groups and between the young and the elderly group to investigate if age has an effect on the outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–85 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Steno Diabetes Center Aarhus

Aarhus, Aarhus N, 8200, Denmark

About this study

BACKGROUND With ageing, skeletal muscles metabolism changes and muscle function declines. This may lead to muscle weakness and increased risk of developing metabolic diseases. Ketone bodies, namely 3-hydroxybutyrate (3-OHB), is an energy substrate that may change the metabolism and improve efficiency of skeletal muscles in a setting of ageing.

OBJECTIVE The study aims to investigate the effects of beta-hydroxybutyrate ingested as a monoester on skeletal muscle function and metabolism during muscle work in young and elderly individuals.

DESIGN Healthy young (20-25 years) and elderly (65-85 years) untrained males will be paired based on age corrected VO2-max. Participants will be evaluated in a double blinded cross-over design on two study days: One day with ketone ester ingestion (D-beta-hydroxybutyrate/D-1,3-butanediol; KetoneAid Pro KE4), one day with ingestion of a volume and calorie and taste matched placebo (lipid emulsion). Blood ketone levels will be kept elevated through a sipping protocol. During both conditions a low glucose dose will be continuously infused to block physiological ketogenesis.

The order of the study days will be randomized and interspaced by at least 4 weeks.

On experimental days, participants meet fasted to perform voluntary contractions with tibialis anterior muscles in a MR compatible dynamometer while oxidative capacity, ATP generation, intramuscular pH, fatiguability and work efficiency is evaluated through 31P-MR spectroscopy.

After, participants will bike at a fixed intensity (~45% of Wmax) while lipid fluxes and glucose oxidation rates are measured by palmitate- and glucose tracer infusions and carbamide-corrected indirect calorimetry over 60 min. This was initially intended for both young and elderly individuals, but only involves the young group, as the elderly group had difficulties completing 60 min cycling.

Lastly on the study days, participants will perform a cycling test as a measure of performance starting at 70 % of Wmax for 5 min thereafter increasing by 10 % of Wmax every 1 min until exhaustion. Muscle biopsies are obtained before (both groups) and just following fixed intensity cycle work (only young group). Adipose tissue biopsies are collected at the beginning of the experimental day (both groups) before ketone/placebo ingestion and after the constant load cycle work (only young group). Blood samples are performed throughout the day to assess substrate levels, hormones and for proteomics analysis.

Before each study day, participant's activity level is measured for 7 days by accelerometry (ActiGraph). Participants will log their diet 3 days prior to each experimental day. Participants are asked to ingest a similar diet 2 days before both experimental days and to withstand from strenuous exercise 2 days prior to both experimental days. Participants are asked not to make any significant changes to their lifestyle while taking part in the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male 20-25 years old (n = 12) OR male 65-85 years old (n = 12)
  • BMI range: 19 to 27
  • Stable weight (< 5% change over last 6 months)
  • Less than 3 x 60 min of structured exercise per week.

Exclusion criteria

  • Medication that affect energy metabolism.
  • Non-MR-compatible metals or electric devices in the body.
  • Anaemia or bleeding disorders.
  • Heart, lung or other disease that affects the subjects ability to exercise.
  • Smoking.
  • Drug abuse.
  • Lack of compliance.
  • Known allergy towards local anaesthetics.
  • Any condition that the principal investigator considers unsuitable for the subject's ability to complete the study.

Treatment and study plan

D-β-hydroxybutyrate/D 1,3 butanediol monoester

Dietary Supplement

Ketone monoester

Primary outcomes

  1. Work efficiency

    Time frame: Over 60 minutes on each of the two experimental days.

    External work performed by the ankle during dorsiflexion per ATP consumed. ATP consumption is assessed by 31P-MRS while external force is measured by the dynamometer.

Secondary outcomes

  1. Oxidative capacity

    Time frame: Over 20 minutes at each of the two experimental days.

    Assessed by 31P-MRS as phosphocreatine resynthesis.

  2. Glucose oxidation rates (only young group)

    Time frame: At 10 minute intervals over the last 30 min of the 90 min fixed intensity cycling on each experimental day.

    Assessed by measuring tracer dilution from blood samples obtained during 3H-glucose infusion while cycling at a fixed intensity.

  3. Palmitate flux (only young group)

    Time frame: At 10 minute intervals over the last 30 min of the 90 min fixed intensity cycling on each experimental day.

    Assessed by measuring tracer dilution from blood samples obtained during 3H-palmitate infusion while cycling at a fixed intensity.

  4. ATP generation

    Time frame: Over 30 minutes at each of the two experimental days.

    ATP generated from different pathways (glycolytic, oxidative, phosphocreatine) assessed by 31P-MRS.

  5. Mitochondrial function

    Time frame: Just before and immediately after the constant load cycling at each of the two experimental days.

    Assessed by high-resolution respirometry on muscle biopsies

  6. Intramuscular pH

    Time frame: Over 60 minutes at each of the two experimental days.

    Measurements at rest rest and during work assessed by 31P-MRS

  7. Blood 3-OHB

    Time frame: During each of the two experimental days

    Blood concentration measured by blood sampling

  8. Blood glucose

    Time frame: During each of the two experimental days

    Blood concentration measured by blood sampling

  9. Blood free fatty acids

    Time frame: During each of the two experimental days

    Blood concentration measured by blood sampling

  10. Cycle performance

    Time frame: 5-8 minutes during each of the two experimental days

    Assessed by a performance test on a bike ergometer with incremental load. The test continues until failure. The test outcome is the power generated at time of failure.

  11. Rating of perceived exertion (only young group)

    Time frame: After 30, 60 and 90 minutes of fixed intensity cycling and just after the incremental performance test.

    Subjective measure of exertion during cycling evaluated by reporting on a number assessment scale (Borg scale (6-20)).

  12. Tibialis anterior fatigue

    Time frame: Over 3 minutes on each of the two experimental days.

    Tibialis anterior fatigue assessed by the dynamometer during 3 minutes of dorsiflexion at a fixed resistance.

  13. Blood growth hormone

    Time frame: During experimental days

    Blood concentration measured by blood sampling

  14. Blood insulin

    Time frame: During each of the two experimental days

    Blood concentration measured by blood sampling

  15. AMPK phosphorylation (only young group)

    Time frame: Just before and immediately after the constant load cycling at each of the two experimental days.

    From muscle biopsies

  16. Blood glucagon

    Time frame: During each of the two experimental days

    Blood concentration measured by blood sampling

  17. Blood pH

    Time frame: During each of the two experimental days

    Assessed from arterial blood samples

  18. Blood catecholamines

    Time frame: During each of the two experimental days

    Blood concentration measured by blood sampling

  19. Blood cortisol

    Time frame: During each of the two experimental days

    Blood concentration measured by blood sampling

  20. Intramuscular lipid content

    Time frame: At the beginning and at the end of each of the two experimental days

    Concentration measured in muscle biopsies

  21. Intramuscular glycogen content

    Time frame: Just before and immediately after the constant load cycling at each of the two experimental days.

    Concentration measured in muscle biopsies

Other outcomes

  1. Blood haemoglobin

    Time frame: Measured at the beginning and the end of each experimental day

    Blood concentration measured by blood sampling

  2. Blood Sodium

    Time frame: Measured at the beginning and the end of each experimental day

    Blood concentration measured by blood sampling

  3. Blood potassium

    Time frame: Measured at the beginning and the end of each experimental day

    Blood concentration measured by blood sampling

  4. Blood creatinine

    Time frame: During each of the two experimental days

    Blood concentration measured by blood sampling

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • AP Moeller Foundation
  • Aarhus University Hospital
  • Danish Diabetes Academy
  • Novo Nordisk A/S

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Feb 17, 2023
Registry last updated
Mar 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.